Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats.
Cannabis use is a hypothesized gateway to subsequent abuse of other drugs such as heroin. We currently assessed whether Delta-9-tetrahydrocannabinol (THC) exposure during adolescence modulates opiate reinforcement and opioid neural systems in adulthood. Long-Evan male rats received THC (1.5 mg/kg intraperitoneally (i.p.)) or vehicle every third day during postnatal days (PNDs) 28-49. Heroin self-administration behavior (fixed ratio-1; 3-h sessions) was studied from young adulthood (PND 57) into full adults (PND 102). THC-pretreated rats showed an upward shift throughout the heroin self-administration acquisition (30 microg/kg/infusion) phase, whereas control animals maintained the same pattern once stable intake was obtained. Heightened opiate sensitivity in THC animals was also evidenced by higher heroin consumption during the maintenance phase (30 and 60 microg/kg/infusion) and greater responding for moderate-low heroin doses (dose-response curve: 7.5, 15, 30, 60, and 100 microg/kg/injection). Specific disturbance of the endogenous opioid system was also apparent in the brain of adults with adolescent THC exposure. Striatal preproenkephalin mRNA expression was exclusively increased in the nucleus accumbens (NAc) shell; the relative elevation of preproenkephalin mRNA in the THC rats was maintained even after heroin self-administration. Moreover, mu opioid receptor (muOR) GTP-coupling was potentiated in mesolimbic and nigrostriatal brainstem regions in THC-pretreated animals. muOR function in the NAc shell was specifically correlated to heroin intake. The current findings support the gateway hypothesis demonstrating that adolescence cannabis exposure has an enduring impact on hedonic processing resulting in enhanced opiate intake, possibly as a consequence of alterations in limbic opioid neuronal populations.
Ellgren
Maria
M
1Department of Clinical Neuroscience, Karolinska Institutet, Psychiatry Section, Stockholm, Sweden.
Spano
Sabrina M
SM
Hurd
Yasmin L
YL
D018712:Analgesics, Non-Narcotic / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000008:administration & dosage*; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D048588:Benzoxazines; D004305:Dose-Response Relationship, Drug; D013759:Dronabinol / Q000494:pharmacology*; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000493:pharmacokinetics; D004745:Enkephalins / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000493:pharmacokinetics; D003932:Heroin / Q000008:administration & dosage*; D017403:In Situ Hybridization; D008032:Limbic System / Q000166:cytology*; D008297:Male; D009025:Morpholines / Q000493:pharmacokinetics; D009281:Naphthalenes / Q000493:pharmacokinetics; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D011869:Radioligand Assay / Q000379:methods; D051381:Rats; D020318:Rats, Long-Evans; D012054:Reinforcement, Psychology; D000077285:Rimonabant; D012646:Self Administration / Q000379:methods; D013460:Sulfur Isotopes / Q000493:pharmacokinetics; D014316:Tritium / Q000493:pharmacokinetics
D018712:Analgesics, Non-Narcotic; D000701:Analgesics, Opioid; D048588:Benzoxazines; D004745:Enkephalins; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011498:Protein Precursors; D011720:Pyrazoles; D013460:Sulfur Isotopes; D014316:Tritium; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D016244:Guanosine 5'-O-(3-Thiotriphosphate); C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D003932:Heroin; D013759:Dronabinol; C033660:preproenkephalin; D000077285:Rimonabant